Senhance robotic radical prostatectomy: A single-centre, 3-year experience

BackgroundSenhance Surgical System is a novel robotic platform used in University Hospital Centre Zagreb since February 2019. In this study, we present our 3-year experience with this platform. Patients and MethodsData were prospectively collected for 200 patients who underwent extraperitoneal robotic radical prostatectomy (RRP) from May 2019 to March 2022. ResultsThe median age of the patients was 65 years, and the prostate-specific antigen was 6.9 ng/mL. Clinically, most of the patients had T1c stage. The estimated blood loss was 250 mL, and there were 6 conversions to laparoscopic and 2 to open prostatectomy. There were 15 early postoperative complications, 11 Clavien-Dindo classification grade I, 3 grade II and 1 grade IV. Functional outcomes in the first 150 patients: 140 patients (93.3%) had good urinary control. Thirteen patients underwent additional oncological treatment. ConclusionRRP performed with the Senhance robotic platform is a feasible and safe procedure with good initial results.

Automated summary

This study presents a 3-year experience with the Senhance Surgical System, a novel robotic platform used in University Hospital Centre Zagreb since February 2019. Data were collected for 200 patients who underwent extraperitoneal robotic radical prostatectomy from May 2019 to March 2022. The results demonstrate that RRP performed with the Senhance robotic platform is a feasible and safe procedure with good initial outcomes.